357 related articles for article (PubMed ID: 9652425)
21. Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy.
Weverling GJ; Lange JM; Jurriaans S; Prins JM; Lukashov VV; Notermans DW; Roos M; Schuitemaker H; Hoetelmans RM; Danner SA; Goudsmit J; de Wolf F
AIDS; 1998 Jul; 12(11):F117-22. PubMed ID: 9708401
[TBL] [Abstract][Full Text] [Related]
22. Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team.
Goodgame JC; Pottage JC; Jablonowski H; Hardy WD; Stein A; Fischl M; Morrow P; Feinberg J; Brothers CH; Vafidis I; Nacci P; Yeo J; Pedneault L
Antivir Ther; 2000 Sep; 5(3):215-25. PubMed ID: 11075942
[TBL] [Abstract][Full Text] [Related]
23. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART).
Hazenberg MD; Stuart JW; Otto SA; Borleffs JC; Boucher CA; de Boer RJ; Miedema F; Hamann D
Blood; 2000 Jan; 95(1):249-55. PubMed ID: 10607709
[TBL] [Abstract][Full Text] [Related]
24. Anti-human immunodeficiency virus type 1 (HIV-1) CD8(+) T-lymphocyte reactivity during combination antiretroviral therapy in HIV-1-infected patients with advanced immunodeficiency.
Rinaldo CR; Huang XL; Fan Z; Margolick JB; Borowski L; Hoji A; Kalinyak C; McMahon DK; Riddler SA; Hildebrand WH; Day RB; Mellors JW
J Virol; 2000 May; 74(9):4127-38. PubMed ID: 10756025
[TBL] [Abstract][Full Text] [Related]
25. Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment.
Landay A; da Silva BA; King MS; Albrecht M; Benson C; Eron J; Glesby M; Gulick R; Hicks C; Kessler H; Murphy R; Thompson M; White AC; Wolfe P; McMillan FI; Hanna GJ
Clin Infect Dis; 2007 Mar; 44(5):749-54. PubMed ID: 17278071
[TBL] [Abstract][Full Text] [Related]
26. Virologic and CD4+ cell responses to new nucleoside regimens: switching to stavudine or adding lamivudine after prolonged zidovudine treatment of human immunodeficiency virus infection. ACTG 302 Study Team. AIDS Clinical Trials Group.
Katzenstein DA; Hughes M; Albrecht M; Hammer S; Para M; Murphy R; Valdez H; Haubrich R; Liou S
AIDS Res Hum Retroviruses; 2000 Jul; 16(11):1031-7. PubMed ID: 10933617
[TBL] [Abstract][Full Text] [Related]
27. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
[TBL] [Abstract][Full Text] [Related]
28. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial.
Matheron S; Descamps D; Boué F; Livrozet JM; Lafeuillade A; Aquilina C; Troisvallets D; Goetschel A; Brun-Vezinet F; Mamet JP; Thiaux C;
Antivir Ther; 2003 Apr; 8(2):163-71. PubMed ID: 12741629
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
Katlama C; Ingrand D; Loveday C; Clumeck N; Mallolas J; Staszewski S; Johnson M; Hill AM; Pearce G; McDade H
JAMA; 1996 Jul; 276(2):118-25. PubMed ID: 8656503
[TBL] [Abstract][Full Text] [Related]
30. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial.
Arribas JR; Girard PM; Landman R; Pich J; Mallolas J; Martínez-Rebollar M; Zamora FX; Estrada V; Crespo M; Podzamczer D; Portilla J; Dronda F; Iribarren JA; Domingo P; Pulido F; Montero M; Knobel H; Cabié A; Weiss L; Gatell JM;
Lancet Infect Dis; 2015 Jul; 15(7):785-92. PubMed ID: 26062880
[TBL] [Abstract][Full Text] [Related]
31. Abacavir/lamivudine/zidovudine maintenance after standard induction in antiretroviral therapy-naïve patients: FREE randomized trial interim results.
Sprenger HG; Langebeek N; Mulder PG; Ten Napel CH; Vriesendorp R; Hoepelman AI; Legrand JC; Koopmans PP; Van Kasteren ME; Bravenboer B; Ten Kate RW; Groeneveld PH; van der Werf TS; Gisolf EH; Richter C
AIDS Patient Care STDS; 2010 Jun; 24(6):361-6. PubMed ID: 20515418
[TBL] [Abstract][Full Text] [Related]
32. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
Murphy RL
Antivir Ther; 1999; 4 Suppl 3():85-7. PubMed ID: 16021877
[TBL] [Abstract][Full Text] [Related]
33. Combination antiretroviral therapy including ritonavir in children infected with human immunodeficiency.
Thuret I; Michel G; Chambost H; Tamalet C; Giraud P; Brunet C; Perrimond H
AIDS; 1999 Jan; 13(1):81-7. PubMed ID: 10207548
[TBL] [Abstract][Full Text] [Related]
34. Alteration of complement protein levels after antiretroviral therapy in HIV-infected persons.
Spear GT; Olinger G; Sullivan BL; Landay AL; Kessler H; Connick E; Kuritzkes D; St Clair M; Spritzler J; Wu H; Lederman MM
AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1713-5. PubMed ID: 10606095
[No Abstract] [Full Text] [Related]
35. Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia.
Zaunders JJ; Cunningham PH; Kelleher AD; Kaufmann GR; Jaramillo AB; Wright R; Smith D; Grey P; Vizzard J; Carr A; Cooper DA
J Infect Dis; 1999 Aug; 180(2):320-9. PubMed ID: 10395845
[TBL] [Abstract][Full Text] [Related]
36. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response.
Connick E; Lederman MM; Kotzin BL; Spritzler J; Kuritzkes DR; St Clair M; Sevin AD; Fox L; Chiozzi MH; Leonard JM; Rousseau F; D'Arc Roe J; Martinez A; Kessler H; Landay A
J Infect Dis; 2000 Jan; 181(1):358-63. PubMed ID: 10608789
[TBL] [Abstract][Full Text] [Related]
37. Long-term evaluation of T-cell subset changes after effective combination antiretroviral therapy during asymptomatic HIV-infection.
Bisset LR; Cone RW; Fischer M; Battegay M; Vernazza PL; Dubs RW; Weber R; Grob PJ; Opravil M;
J Acquir Immune Defic Syndr; 2001 Jul; 27(3):266-71. PubMed ID: 11464146
[TBL] [Abstract][Full Text] [Related]
38. Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial.
Miró JM; Manzardo C; Pich J; Domingo P; Ferrer E; Arribas JR; Ribera E; Arrizabalaga J; Loncá M; Cruceta A; de Lazzari E; Fuster M; Podzamczer D; Plana M; Gatell JM;
AIDS Res Hum Retroviruses; 2010 Jul; 26(7):747-57. PubMed ID: 20624069
[TBL] [Abstract][Full Text] [Related]
39. Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.
Henry K; Wallace RJ; Bellman PC; Norris D; Fisher RL; Ross LL; Liao Q; Shaefer MS;
J Infect Dis; 2001 Feb; 183(4):571-8. PubMed ID: 11170982
[TBL] [Abstract][Full Text] [Related]
40. Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages.
Sleasman JW; Nelson RP; Goodenow MM; Wilfret D; Hutson A; Baseler M; Zuckerman J; Pizzo PA; Mueller BU
J Pediatr; 1999 May; 134(5):597-606. PubMed ID: 10228296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]